Naloxegol (Movantik) and Oral Methylnaltrexone (Relistor) Have Similar Efficacy
Based on current evidence, naloxegol and oral methylnaltrexone appear to have comparable efficacy for treating opioid-induced constipation, though naloxegol has stronger guideline support (strong recommendation with moderate-quality evidence) compared to methylnaltrexone (conditional recommendation with low-quality evidence). 1, 2
Guideline Recommendations
The 2019 AGA guidelines provide clear differentiation in recommendation strength:
- Naloxegol: Strong recommendation with moderate-quality evidence 1
- Oral Methylnaltrexone: Conditional recommendation with low-quality evidence 2
This difference in recommendation strength reflects the quality and quantity of supporting data rather than necessarily indicating superior clinical efficacy.
Head-to-Head Comparative Data
Recent real-world studies demonstrate noninferiority between these agents:
- A 2024 ICU study (n=161) found naloxegol noninferior to subcutaneous methylnaltrexone, with median time to first bowel movement of 23.7 hours vs 18.3 hours respectively 3
- A 2023 multicenter hospital study (n=330) confirmed naloxegol met prespecified noninferiority margins for bowel movement within 48 hours (risk difference -4.6%) 4
Both studies showed similar numbers of bowel movements over 72 hours (approximately 3.8-3.9 per patient) 3.
Practical Considerations
Route of administration matters clinically:
- Naloxegol is oral only 5
- Methylnaltrexone is available both orally and subcutaneously 6
- The oral route is generally preferred for convenience and patient acceptance
Cost differences are substantial:
- Naloxegol costs approximately $21.74 per bowel movement vs $170.00 for methylnaltrexone using wholesale acquisition cost 3
- Naloxegol saved $193.16 per patient in hospital settings 4
Mechanism and Safety Profile
Both agents work as peripherally-acting mu-opioid receptor antagonists (PAMORAs) with limited CNS penetration:
- Naloxegol: PEGylated naloxone derivative, P-glycoprotein substrate limiting blood-brain barrier crossing 5
- Methylnaltrexone: Quaternary ammonium structure preventing blood-brain barrier penetration 6
Neither agent interferes with central opioid analgesia at recommended doses. Adverse effects are predominantly gastrointestinal (abdominal pain, diarrhea) and generally mild to moderate 1, 7.
Clinical Algorithm
For laxative-refractory OIC, choose based on:
- First-line PAMORA: Naloxegol 25 mg daily (stronger evidence base, lower cost)
- Alternative if oral route unavailable: Subcutaneous methylnaltrexone
- Renal impairment (CrCl <60): Reduce both agents' doses 6, 5
- Hepatic impairment (moderate-severe): Reduce methylnaltrexone tablets; naloxegol requires no adjustment for mild-moderate impairment 6, 5
Common pitfall: Starting PAMORAs before adequate laxative trial. Both guidelines emphasize laxatives as first-line therapy 1, 2.